Catalyst Pharmaceuticals Inc (CPRX) is now in the Fair zone, suggesting that its current forward PE ratio of 15.35 is considered Fairly compared with the five-year average of 14.35. The fair price of Catalyst Pharmaceuticals Inc (CPRX) is between 21.46 to 32.04 according to relative valuation method.

Relative Value

Fair Zone

21.46-32.04

Current Price：23.88

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Catalyst Pharmaceuticals Inc (CPRX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Catalyst Pharmaceuticals Inc (CPRX) has a current Price-to-Book (P/B) ratio of 3.10. Compared to its 3-year average P/B ratio of 3.78, the current P/B ratio is approximately -18.03% higher. Relative to its 5-year average P/B ratio of 3.88, the current P/B ratio is about -20.04% higher. Catalyst Pharmaceuticals Inc (CPRX) has a Forward Free Cash Flow (FCF) yield of approximately 8.24%. Compared to its 3-year average FCF yield of 4.15%, the current FCF yield is approximately 98.75% lower. Relative to its 5-year average FCF yield of 5.55%, the current FCF yield is about 48.63% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CPRX competitors is 34.72, providing a benchmark for relative valuation. Catalyst Pharmaceuticals Inc Corp (CPRX.O) exhibits a P/S ratio of 4.81, which is -86.15% above the industry average. Given its robust revenue growth of 7.61%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CPRX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CPRX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CPRX currently overvalued or undervalued?

What is Catalyst Pharmaceuticals Inc (CPRX) fair value?

CPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Catalyst Pharmaceuticals Inc (CPRX) is between 21.46 to 32.04 according to relative valuation method.

How does CPRX's valuation metrics compare to the industry average?

The average P/S ratio for CPRX's competitors is 34.72, providing a benchmark for relative valuation. Catalyst Pharmaceuticals Inc Corp (CPRX) exhibits a P/S ratio of 4.81, which is -86.15% above the industry average. Given its robust revenue growth of 7.61%, this premium appears unsustainable.

What is the current P/B ratio for Catalyst Pharmaceuticals Inc (CPRX) as of Mar 03 2026?

As of Mar 03 2026, Catalyst Pharmaceuticals Inc (CPRX) has a P/B ratio of 3.10. This indicates that the market values CPRX at 3.10 times its book value.

What is the current FCF Yield for Catalyst Pharmaceuticals Inc (CPRX) as of Mar 03 2026?

As of Mar 03 2026, Catalyst Pharmaceuticals Inc (CPRX) has a FCF Yield of 8.24%. This means that for every dollar of Catalyst Pharmaceuticals Inc's market capitalization, the company generates 8.24 cents in free cash flow.

What is the current Forward P/E ratio for Catalyst Pharmaceuticals Inc (CPRX) as of Mar 03 2026?

As of Mar 03 2026, Catalyst Pharmaceuticals Inc (CPRX) has a Forward P/E ratio of 15.35. This means the market is willing to pay $15.35 for every dollar of Catalyst Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Catalyst Pharmaceuticals Inc (CPRX) as of Mar 03 2026?

As of Mar 03 2026, Catalyst Pharmaceuticals Inc (CPRX) has a Forward P/S ratio of 4.81. This means the market is valuing CPRX at $4.81 for every dollar of expected revenue over the next 12 months.

CPRX Valuation